AVO Aveon Group LP Com USD0.01

Advanced Medical Optics, Inc. Announces Filing of Registration Statement on Form S-3 SANTA ANA, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Advanced Medical Optics, Inc. (AMO) (NYSE:AVO), today announced that it had filed a registration statement on Form S-3 with the Securities and Exchange Commission (SEC). The registration statement relates to the resale by holders of AMO's 2.50% Convertible Senior Subordinated Notes due 2024, and the shares of AMO's common stock issuable upon conversion of the notes. AMO's initial issuance of the notes, in an aggregate principal amount of $350 million, was completed on June 22, 2004. A written prospectus, when available, meeting the requirements of Section 10 of the Securities Act may be obtained from AMO at 1700 E. St. Andrew Place, Santa Ana, California 92705, Attention: Investor Relations. A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. About Advanced Medical Optics Advanced Medical Optics, Inc. (AMO) is a global leader in the development, manufacturing and marketing of ophthalmic surgical and eye care products. The company focuses on developing a broad suite of innovative technologies and devices to address a wide range of eye disorders. Products in the ophthalmic surgical line include foldable intraocular lenses, phacoemulsification systems, viscoelastics and related products used in cataract surgery, and microkeratomes used in LASIK procedures for refractive error correction. AMO owns or has the rights to such ophthalmic surgical product brands as Phacoflex(R), Clariflex(R), Array(R), Sensar(R), CeeOn(R) and Tecnis(R) intraocular lenses, Sovereign(R) and Sovereign(R) Compact phacoemulsification systems with WhiteStar(TM) technology, Amadeus(TM) microkeratome, Healon(R) and Vitrax(R) viscoelastics, and the Baerveldt(R) glaucoma shunt. Products in the contact lens care line include disinfecting solutions, daily cleaners, enzymatic cleaners and lens rewetting drops. Among the contact lens care product brands the company possesses are COMPLETE(R) Moisture PLUS(TM), COMPLETE(R) Blink-N-Clean(R), Consept(R)F, Consept(R) 1 Step, Oxysept(R) 1 Step, UltraCare(R), Ultrazyme(R), Total Care(R) and blink(TM) branded products. Amadeus is a licensed product of, and a trademark of, SIS, Ltd. AMO is based in Santa Ana, California, and employs approximately 2,800 worldwide. The company has operations in about 20 countries and markets products in approximately 60 countries. Forward-Looking Statements This press release contains forward-looking statements about AMO that involve risks and uncertainties, including those relating to the effectiveness of the registration statement. All forward-looking statements in this press release are based on estimates and assumptions and represent AMO's judgment only as of the date of this press release. Actual results may differ from current expectations. Therefore, the reader is cautioned not to rely on these forward-looking statements. AMO disclaims any intent or obligation to update these forward-looking statements. For further information, please contact: Investors, Sheree Aronson of Advanced Medical Optics, Inc., +1-714-247-8290, . DATASOURCE: Advanced Medical Optics, Inc. CONTACT: Investors, Sheree Aronson of Advanced Medical Optics, Inc., +1-714-247-8290,

Copyright